Johnson & Johnson $JNJ Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 643,935 shares of the company’s stock after selling 19,732 shares during the period. Johnson & Johnson comprises approximately 2.1% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 9th largest position. Douglas Lane & Associates LLC’s holdings in Johnson & Johnson were worth $170,475,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Auto Owners Insurance Co boosted its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Johnson & Johnson by 8.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after buying an additional 1,376,828 shares during the last quarter. Deutsche Bank AG raised its position in Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Finally, Amundi increased its position in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong long-term psoriasis data: Johnson & Johnson reported two-year Phase 3 results for ICOTYDE® (icotrokinra), with nearly three-quarters of adults and adolescents achieving clear or almost clear skin and a favorable safety profile. The data support the drug’s commercial prospects and could strengthen JNJ’s pharmaceutical pipeline. ICOTYDE two-year data
• Positive Sentiment: Analyst support: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. Separate commentary highlights JNJ as a potential faster-growth healthcare company, helping support investor confidence despite its premium valuation. Guggenheim Buy rating
• Positive Sentiment: Income-investor appeal: Articles continue to feature JNJ as a Dividend Aristocrat with a long record of dividend growth and comparatively reliable cash generation. That defensive profile may attract investors seeking stability amid healthcare-sector uncertainty. Healthcare Dividend Aristocrats
• Neutral Sentiment: Earnings expectations remain constructive: Analysts are looking for another earnings beat, and previews focus on September-quarter operating metrics. However, these reports are forecasts rather than confirmed results, leaving execution and forward guidance as the next catalysts. JNJ Q3 earnings preview
• Negative Sentiment: Patent-cliff risk persists: Upcoming patent expirations for cancer medicines Imbruvica and Darzalex could pressure pharmaceutical revenue over the next several years. Management’s pipeline investments and dealmaking may mitigate the impact, but investors remain focused on whether new products can replace lost exclusivity. JNJ patent cliff

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, September 22nd. TD Cowen raised their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $276.22.

Johnson & Johnson Trading Up 1.8%

NYSE JNJ traded up $4.52 during trading hours on Friday, hitting $261.00. 1,827,529 shares of the company were exchanged, compared to its average volume of 7,939,630. The stock has a market cap of $628.99 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 2.59 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average price of $265.73 and a 200 day moving average price of $248.93. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts forecast that Johnson & Johnson will post 11.3 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 62.11%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.